JPRN-jRCT2031220587进行中（未招募）2 期
A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysis
Mita Seiji0 个研究点目标入组 150 人开始时间: 2023年1月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 < 80age old（—）
- 性别
- All
入选标准
- •1. Hyperphosphatemia patients (outpatients) with chronic kidney disease receiving hemodialysis (HD or HDF) 3 times a week for at least 12 weeks prior to Visit 1 (Week -4)
- •2. Patients aged >=18 to <80 years at the time of obtaining informed consent
- •3. Patients with a serum phosphorus concentration of >= 3.5 mg/dL and =< 6.0 mg/dL at Visit 1 (Week -4)
排除标准
- •1. Patients with confirmed serum intact PTH concentration >500 pg/mL from Visit 1 (Week -4) to Visit 5 (Week 0)
- •2. Patients with serum phosphorus concentration >=10.0 mg/dL from Visit 2 (Week -3) to Visit 5 (Week 0)
- •3. Patients who have undergone previous parathyroid intervention (PTx, PEIT, etc.)
研究者
相似试验
已完成
2 期
A phase 2 study of TAS-303 in female patients with stress urinary incontinenceStress urinary incontinenceJPRN-jRCT2080225307Taiho Pharmaceutical Co., Ltd.186
未知
2 期
A phase 2, randomized, placebo-controlled, double-blind, crossover study of DS-8500a to evaluate the effects on pancreatic beta cell function in Japanese patients with type 2 diabetes mellitusType 2 Diabetes MellitusJPRN-jRCT2080223072DAIICHI SANKYO CO., LTD.20
进行中（未招募）
1 期
A phase II randomized, placebo-controlled, double-blind, dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamic dose response relationship of IFX-1 in patients undergoing complex cardiac surgery (CARDIAC)Prevention of organ dysfunction induced by inflammatory response after complex cardiac surgeryMedDRA version: 20.0Level: PTClassification code 10063101Term: Post procedural inflammationSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 20.0Level: LLTClassification code 10062357Term: SIRSSystem Organ Class: 100000004867EUCTR2015-003036-12-DEInflaRx GmbH
进行中（未招募）
1 期
A Clinical Study to evaluate Ladarixin as an additional therapy to improve glycemic control in overweight insulin resistance patients with type 1 diabetes.EUCTR2022-000743-68-ITDOMPé FARMACEUTICI S.P.A.86
进行中（未招募）
1 期
A phase II randomized, placebo-controlled, double-blind, dose controlled trial in patients suffering from early, newly developing abdominal or pulmonary derived septic organ dysfunction to evaluate safety, pharmacokinetics, pharmacodynamics and to estimate efficacy of the new humanized monoclonal i.v. administered antibody CaCP29EUCTR2013-001037-40-DEInflaRx GmbH72